NEW YORK, Jan. 22-Compugen has granted a license to Diagnostic Products Corporation to develop new assays for prostate cancer, the two companies said today.
The license, which covers two previously unidentified prostate-specific proteins, gives DPC the exclusive right to develop and commercialize assays for screening, detection and monitoring of cancer.
Compugen will receive milestone payments and royalties in the deal.
Compugen announced that it had discovered these two proteins last February. Both are encoded by mRNA splice variants of the genes for prostate-specific antigen.
Financial details of this agreement were not disclosed.
Diagnostic Products Corporation, based in Los Angeles, produces immunodiagnostic tests and manufactures laboratory instruments for diagnostics.